ВОПРОСЫ БЕЗОПАСНОСТИ ЛЕЧЕНИЯ СТАТИНАМИ
Аннотация
Резюме. В статье обсуждаются практически важные вопросы безопасности длительного применения статинов у пациентов с высоким и очень высоким уровнем сердечнососудистого риска, включая данные о возможности статин-ассоциированных случаев возникновения сахарного диабета, онкологических проблем, когнитивных и офтальмологических нарушений. Приводятся рекомендации ведущих экспертов по обеспечению мышечной и печеночной безопасности статинотерапии. Системный поиск литературы проводили по базам данных Scopus, Web of Science, MedLine, elibrary, РИНЦ и другим.
Литература
1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза / Кухарчук В.В., Коновалов Г.А., Сусеков А.В., и др. / Российские рекомендации (V пересмотр). – М., 2012. – 50 с. Доступно по: www.scardio.ru/content/Guidelines/ rek_lipid_2012.pdf
2. Ивашкин В.Т., Драпкина О.М. Рекомендации по диагностике и лечению неалкогольной жировой болезни печени. – М., 2012. – 27 с. [Электронный ресурс]: http://www.gastro-j.ru/article/718-h2-klinicheskie-re82komendatsii-nbsp-po-diagnostike-i-lecheniyu-nealkogolnoy-zhirovoy-bolezni-pech/
3. A clinician’s guide to statin drug-drug interactions / K.A. Kellick, M. Bottorff, P.P. Toth // J. Clin. Lipidol.– 2014. – Vol. 8. – S. 30-46
4. Antman E.M. Clinical practice guidelines for chronic cardiovascular disorders: roadmap for the future // J. Amer. Med. Ass. – 2014. –Vol. 311, N 12. – P. 1195-1196
5. American Diabetes Association Standards of Medical Care in Diabetes–2016 // Diabetes Care. – 2016. – Vol. 39 (Suppl 1). – 112 p. [Электронный ресурс]: http://healthmonix.com/ADAWebcastSOC2016/common/files/Clinical%20Diabetes%20abridged.pdf
6. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease / M. Sano, K.L. Bell, D. Glasko et al. // Neurology.– 2011. – Vol. 77. – P. 556-563
7. ACC/AHA 2015 Focused Update of Secondary Prevention Lipid Performance Measures/ J.P. Drozda, T.B. Ferguson, H. Jneid et al. // Amer. Coll. Cardiol. – 2016. – Vol. 67, N 5. – P. 558-587. [Электронный ресурс]: doi:10.1016/j. jacc.2015.02.003
8. An assessment by the Statin Cognitive Safety Task Force: 2014 update / C.H. Rojas-Fernandez, L.B. Goldstein, A.I. Levey et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 5-16
9. An assessment by the Statin Diabetes Safety Task Force: 2014 update / K.C. Maki, P.M. Ridker, W.V. Brown et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 17-29
10. An assessment by the Statin Liver Safety Task Force: 2014 update / H.Bays,D.E. Cohen, N. Chalasani, S. A. Harrison // J. Clin. Lipidol. – 2014.–Vol. 8. – S. 47-57
11. An assessment by the Statin Muscle Safety Task Force: 2014 update / R. S. Rosenson, S. K. Baker, T.A. Jacobson et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 58-71
12. An assessment by the Statin Intolerance Panel: 2014 update / J.R. Guyton, H.E. Bays, S.M. Grundy, T.A. Jacobson // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 72-81
13. Cholesterol lowering in intermediate-risk persons without cardiovascular disease / Yusuf S., Bosch J., Dagenais G. et al. // N. Engl. J. Med. – 2016. – Vol. 374. – P. 2021-2031
14. Discontinuation of statins in routine care settings: a cohort study / Zhang H, Plutzky J, Skentzos S et al.// Ann. Intern. Med. – 2013. – Vol. 158. – P. 526–534
15. Effect of statins on skeletal muscle function/ B.A. Parker, J.A. Capizzi, A.S. Grimaldi et al. // Circulation. – 2013. – 127. – P. 96-103
16. ESC/EAS 2016 Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Catapano A.L., Graham I., De Backer G. et al. with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). [Электронный ре- сурс] doi: http://dx.doi.org/10.1093/eurheartj/ehw272
17. European Guidelines 2016 on cardiovascular disease prevention in clinical practice / M.F. Piepoli, A.W., S. Agewall et al. // Eur. Heart J. – 2016. – Vol. 37, N 29. – P. 2315-2381
18. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin / A.M. Laties, C.L. Shear, E.A. Lippa et al. // Amer. J. Cardiol. – 1991. – Vol. 67. – P. 447-453
19. Hippisley-Cox J. Unintended eff ects of statins in men and women in England and Wales: population based cohort study using the Q. Research database / J. Hippisley-Cox, C. Coupland // Brit.Med. J. – 2010. – Vol .340. – P. 2197
20. Interpretation of the evidence for the efficacy and safety of statin therapy / R. Collins, C. Reith, J Emberson, et al. // The Lancet. – 2016. – Vol. 388, N 10059. – P. 2532-2561. [Электронный ресурс]: http://dx.doi.org/10.1016/ S0140-6736(16)31357-5
21. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study / E. Bruckert, G. Hayem, S. Dejager et al. // Cardiovasc. Drugs Ther. – 2005. – Vol. 19. – P. 403–414
22. NLA Task Force on Statin Safety - 2014 update / T.A. Jacobson // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 1-4
23. Original Contribution An assessment by the Statin Muscle Safety Task Force: 2014 update / R.S. Rosenson, S.K. Baker, T. A. Jacobson et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 58-71
24. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe / H.H. Feldman, R.S. Doody, M. Kivipelto et al. // Neurology. – 2010. – Vol. 74. – P. 956-964
25. Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: a randomized controlled trial / K. Ueshima, H. Itoh, N. Kanazawa et al. // J. Atheroscler. Thromb. – 2016. – Vol. 23. – P. 976-990
26. Relationship of ethnic origin, gender, and age to blood creatine kinase levels / R.C. Neal, K.C. Ferdinand, J. Ycas, E. Miller // Amer. J. Med. – 2009. – Vol. 122. – P. 73-78
27. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study / T.R. Pedersen, K. Berg, T.J. Cook et al. // Arch. Intern. Med. – 1996. – Vol. 156. – P. 2085-2092
28. Spence J.D. Statins and cataracts: reverse causality? // Can. J. Cardiol. 2015. – Vol. 31. – P. 691
29. Systematic review of statin-induced muscle problems in clinical trials / H.V. Ganga, H.B. Slim, P.D. Thompson // Amer. Heart J. – 2014. – Vol. 168, N 1. – P. 6-15
2. Ивашкин В.Т., Драпкина О.М. Рекомендации по диагностике и лечению неалкогольной жировой болезни печени. – М., 2012. – 27 с. [Электронный ресурс]: http://www.gastro-j.ru/article/718-h2-klinicheskie-re82komendatsii-nbsp-po-diagnostike-i-lecheniyu-nealkogolnoy-zhirovoy-bolezni-pech/
3. A clinician’s guide to statin drug-drug interactions / K.A. Kellick, M. Bottorff, P.P. Toth // J. Clin. Lipidol.– 2014. – Vol. 8. – S. 30-46
4. Antman E.M. Clinical practice guidelines for chronic cardiovascular disorders: roadmap for the future // J. Amer. Med. Ass. – 2014. –Vol. 311, N 12. – P. 1195-1196
5. American Diabetes Association Standards of Medical Care in Diabetes–2016 // Diabetes Care. – 2016. – Vol. 39 (Suppl 1). – 112 p. [Электронный ресурс]: http://healthmonix.com/ADAWebcastSOC2016/common/files/Clinical%20Diabetes%20abridged.pdf
6. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease / M. Sano, K.L. Bell, D. Glasko et al. // Neurology.– 2011. – Vol. 77. – P. 556-563
7. ACC/AHA 2015 Focused Update of Secondary Prevention Lipid Performance Measures/ J.P. Drozda, T.B. Ferguson, H. Jneid et al. // Amer. Coll. Cardiol. – 2016. – Vol. 67, N 5. – P. 558-587. [Электронный ресурс]: doi:10.1016/j. jacc.2015.02.003
8. An assessment by the Statin Cognitive Safety Task Force: 2014 update / C.H. Rojas-Fernandez, L.B. Goldstein, A.I. Levey et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 5-16
9. An assessment by the Statin Diabetes Safety Task Force: 2014 update / K.C. Maki, P.M. Ridker, W.V. Brown et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 17-29
10. An assessment by the Statin Liver Safety Task Force: 2014 update / H.Bays,D.E. Cohen, N. Chalasani, S. A. Harrison // J. Clin. Lipidol. – 2014.–Vol. 8. – S. 47-57
11. An assessment by the Statin Muscle Safety Task Force: 2014 update / R. S. Rosenson, S. K. Baker, T.A. Jacobson et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 58-71
12. An assessment by the Statin Intolerance Panel: 2014 update / J.R. Guyton, H.E. Bays, S.M. Grundy, T.A. Jacobson // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 72-81
13. Cholesterol lowering in intermediate-risk persons without cardiovascular disease / Yusuf S., Bosch J., Dagenais G. et al. // N. Engl. J. Med. – 2016. – Vol. 374. – P. 2021-2031
14. Discontinuation of statins in routine care settings: a cohort study / Zhang H, Plutzky J, Skentzos S et al.// Ann. Intern. Med. – 2013. – Vol. 158. – P. 526–534
15. Effect of statins on skeletal muscle function/ B.A. Parker, J.A. Capizzi, A.S. Grimaldi et al. // Circulation. – 2013. – 127. – P. 96-103
16. ESC/EAS 2016 Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Catapano A.L., Graham I., De Backer G. et al. with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). [Электронный ре- сурс] doi: http://dx.doi.org/10.1093/eurheartj/ehw272
17. European Guidelines 2016 on cardiovascular disease prevention in clinical practice / M.F. Piepoli, A.W., S. Agewall et al. // Eur. Heart J. – 2016. – Vol. 37, N 29. – P. 2315-2381
18. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin / A.M. Laties, C.L. Shear, E.A. Lippa et al. // Amer. J. Cardiol. – 1991. – Vol. 67. – P. 447-453
19. Hippisley-Cox J. Unintended eff ects of statins in men and women in England and Wales: population based cohort study using the Q. Research database / J. Hippisley-Cox, C. Coupland // Brit.Med. J. – 2010. – Vol .340. – P. 2197
20. Interpretation of the evidence for the efficacy and safety of statin therapy / R. Collins, C. Reith, J Emberson, et al. // The Lancet. – 2016. – Vol. 388, N 10059. – P. 2532-2561. [Электронный ресурс]: http://dx.doi.org/10.1016/ S0140-6736(16)31357-5
21. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study / E. Bruckert, G. Hayem, S. Dejager et al. // Cardiovasc. Drugs Ther. – 2005. – Vol. 19. – P. 403–414
22. NLA Task Force on Statin Safety - 2014 update / T.A. Jacobson // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 1-4
23. Original Contribution An assessment by the Statin Muscle Safety Task Force: 2014 update / R.S. Rosenson, S.K. Baker, T. A. Jacobson et al. // J. Clin. Lipidol. – 2014. – Vol. 8. – S. 58-71
24. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe / H.H. Feldman, R.S. Doody, M. Kivipelto et al. // Neurology. – 2010. – Vol. 74. – P. 956-964
25. Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: a randomized controlled trial / K. Ueshima, H. Itoh, N. Kanazawa et al. // J. Atheroscler. Thromb. – 2016. – Vol. 23. – P. 976-990
26. Relationship of ethnic origin, gender, and age to blood creatine kinase levels / R.C. Neal, K.C. Ferdinand, J. Ycas, E. Miller // Amer. J. Med. – 2009. – Vol. 122. – P. 73-78
27. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study / T.R. Pedersen, K. Berg, T.J. Cook et al. // Arch. Intern. Med. – 1996. – Vol. 156. – P. 2085-2092
28. Spence J.D. Statins and cataracts: reverse causality? // Can. J. Cardiol. 2015. – Vol. 31. – P. 691
29. Systematic review of statin-induced muscle problems in clinical trials / H.V. Ganga, H.B. Slim, P.D. Thompson // Amer. Heart J. – 2014. – Vol. 168, N 1. – P. 6-15
Опубликована
2017-10-02
Как цитировать
БАГРИЙ, А. Э. et al.
ВОПРОСЫ БЕЗОПАСНОСТИ ЛЕЧЕНИЯ СТАТИНАМИ.
Университетская клиника, [S.l.], v. 12, n. 1, p. 74 - 82, окт. 2017.
ISSN 1819-0464. Доступно на: <http://journal.dnmu.ru/index.php/UC/article/view/69>. Дата доступа: 26 апр. 2024
Раздел
В помощь практикующему врачу
